Serotonergic function and late luteal phase dysphoric disorder.
Thirty-eight subjects who met criteria for the DSM-III-R diagnosis late luteal phase dysphoric disorder (LLPDD) were compared with 18 controls in 5-HT uptake kinetics of the platelets in the premenstrual (day 26) as well as in the postmenstrual phase (day 4) of the cycle. Furthermore, 5-hydroxytryptophan (5-HTP) was administered to LLPDD patients and controls in both phases of the cycle, to investigate pituitary sensitivity for serotonin. Plasma samples for the measurement of cortisol and beta-endorphin were taken before and after oral administration of 200 mg 5-HTP, and considered as an index of pituitary-adrenal function. LLPDD was not associated with a lower platelet 5-HT uptake and content in the premenstrual phase of the cycle, compared with the postmenstrual phase. Patients appeared not to be different from controls in 5-HT uptake kinetics of platelets in the premenstrual phase of the cycle. No main differences were observed between LLPDD patients and controls in their ability to respond with secretion of cortisol and beta-endorphin to 5-HTP stimulation, either in the premenstrual, or in the postmenstrual phase. This observation could not be attributed to differences in 5-HTP metabolism. The findings of the present study do not support a specific role for 5-HT in the pathophysiology LLPDD.
Veeninga
A T
AT
Psychiatric Hospital De Grote Rivieren, Dordrecht, The Netherlands.
Westenberg
H G
HG
D006916:5-Hydroxytryptophan; D000328:Adult; D001792:Blood Platelets / Q000378:metabolism; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008183:Luteal Phase; D011293:Premenstrual Syndrome / Q000503:physiopathology*; D012701:Serotonin / Q000493:pharmacokinetics / Q000502:physiology*; D001615:beta-Endorphin / Q000097:blood
D012701:Serotonin; D001615:beta-Endorphin; D006916:5-Hydroxytryptophan; D006854:Hydrocortisone